Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection

Part of paid clinical trials in New York, New York.

Sponsor
Memorial Sloan Kettering Cancer Center
Study ID
NCT04377659
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Tocilizumab — DRUG
    Participants will receive Tocilizumab 8 mg/kg i.v. at enrollment. Dose will be capped at 800 mg per infusion. If there is no improvement or toxicity, a second dose can be given 24 hrs to 5 days later.

Study Details

The purpose of this study is to find out whether the study drug tocilizumab is an effective treatment for COVID-19 infection.

Key Dates

Start date
May 1, 2020
Status verified
Oct 2022
Primary completion
Oct 28, 2022
Completion
Oct 28, 2022

Study Design

Enrollment
9 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Intubation/Mechanical Ventilation
    Progression of respiratory failure in cohort #1 will be defined as a sustained increase in oxygen requirement or need for intubation/mechanical ventilation
  • Experimental: Respiratory Support
    In cohort #2 progression of respiratory failure will be defined as a need for increasing respiratory support (e.g. FiO2 or PEEP)

Primary Outcome Measure

Progression of Respiratory Failure or Death [ Time Frame: 14 days ]

Locations (1)

FacilityCityStateZIPSite coordinators
Memorial Sloan Kettering Cancer CenterNew YorkNew York10065-

Find similar trials in New York, NY

By condition
COVID-19 / long COVID
By specialty
Infectious disease
By research site
Memorial Sloan Kettering Cancer Center· New York, NY

Related Studies